At the news
? BULLISHIMPACT 8/10 8-K filed Sep 2, 2026 at 21:37 ET
Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, with a concurrent $99.9M PIPE financing. The combined company will operate under the Remix name and pipeline, with Passage's existing assets (Legacy Assets) being divested and their proceeds distributed to Passage's pre-merger shareholders via Contingent Value Rights (CVRs). This is a transformative event that effectively replaces Passage's business with Remix's, making it a new entity for investors.
- Passage Bio is acquiring Remix Therapeutics via a two-step merger, with Remix valued at $226M in equity.
- A concurrent PIPE financing of at least $99.9M is being raised to fund the combined company.
- Passage's existing assets (Legacy Assets) will be sold, with proceeds distributed to pre-merger Passage shareholders through CVRs.
- The combined company will be named Remix Therapeutics, Inc., and Passage's current management will be replaced by Remix's team.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access